← Back to Screener
Apyx Medical Corporation Common Stock (APYX)
Price$4.47
Value ScoreD
Growth ScoreB
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)-4.41%
Price vs S&P 500 (4W)17.02%
VGM Score61.52
Market Capitalization$187.18M
All Metrics
Book Value / Share (Quarterly)$0.31
P/TBV (Annual)4.17x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)5.89%
Cash Flow / Share (Quarterly)$-0.21
Price vs S&P 500 (YTD)11.55%
Gross Margin (TTM)63.15%
Net Profit Margin (TTM)-16.40%
EPS (TTM)$-0.22
10-Day Avg Trading Volume0.15M
EPS Excl Extra (TTM)$-0.22
Revenue Growth (5Y)13.78%
EPS (Annual)$-0.27
ROI (Annual)-22.68%
Gross Margin (Annual)62.53%
Net Profit Margin (5Y Avg)-37.82%
Cash / Share (Quarterly)$0.74
Revenue Growth QoQ (YoY)32.45%
ROA (Last FY)-16.77%
Revenue Growth TTM (YoY)18.22%
EBITD / Share (TTM)$-0.09
ROE (5Y Avg)-80.45%
Operating Margin (TTM)-7.70%
Cash Flow / Share (Annual)$-0.22
P/B Ratio14.59x
P/B Ratio (Quarterly)12.03x
Net Income / Employee (Annual)$-54,700
EV / Revenue (TTM)3.42x
Net Interest Coverage (TTM)-1.42x
ROA (TTM)-14.94%
EV / EBITDA (TTM)277.04x
EPS Incl Extra (Annual)$-0.27
Current Ratio (Annual)5.00x
Quick Ratio (Quarterly)4.65x
3-Month Avg Trading Volume0.16M
52-Week Price Return158.43%
Revenue / Employee (TTM)$272,700
Tangible BV / Share (Quarterly)$2.38
P/S Ratio (Annual)3.54x
Asset Turnover (Annual)0.79x
52-Week High$4.50
Operating Margin (5Y Avg)-34.59%
EPS Excl Extra (Annual)$-0.27
CapEx CAGR (5Y)13.94%
Tangible BV CAGR (5Y)-0.37%
26-Week Price Return6.98%
Quick Ratio (Annual)4.16x
13-Week Price Return30.00%
Total Debt / Equity (Annual)2.40x
Current Ratio (Quarterly)5.80x
Enterprise Value$191.15M
Revenue / Share Growth (5Y)9.68%
Asset Turnover (TTM)0.91x
Book Value / Share Growth (5Y)-28.47%
Revenue / Employee (Annual)$257,800
Inventory Turnover (Annual)2.45x
Pretax Margin (Annual)-20.50%
Cash / Share (Annual)$0.76
3-Month Return Std Dev92.51%
Gross Margin (5Y Avg)64.55%
Net Income / Employee (TTM)$-44,700
ROE (Last FY)-77.10%
Net Interest Coverage (Annual)-0.92x
EPS Basic Excl Extra (Annual)$-0.27
P/FCF (TTM)53.18x
Receivables Turnover (TTM)4.58x
Total Debt / Equity (Quarterly)2.74x
EPS Incl Extra (TTM)$-0.22
Receivables Turnover (Annual)3.26x
ROI (TTM)-20.43%
P/S Ratio (TTM)3.35x
Pretax Margin (5Y Avg)-38.32%
Revenue / Share (Annual)$1.29
Tangible BV / Share (Annual)$0.62
Price vs S&P 500 (52W)131.39%
Year-to-Date Return22.57%
5-Day Price Return7.38%
EPS Normalized (Annual)$-0.27
ROA (5Y Avg)-28.68%
Net Profit Margin (Annual)-21.22%
Month-to-Date Return7.38%
Cash Flow / Share (TTM)$-0.42
EBITD / Share (Annual)$-0.14
Operating Margin (Annual)-12.20%
LT Debt / Equity (Annual)2.40x
ROI (5Y Avg)-38.45%
LT Debt / Equity (Quarterly)2.73x
EPS Basic Excl Extra (TTM)$-0.22
P/TBV (Quarterly)2.92x
P/B Ratio (Annual)9.88x
Inventory Turnover (TTM)2.39x
Pretax Margin (TTM)-15.58%
Book Value / Share (Annual)$0.35
Price vs S&P 500 (13W)19.50%
Beta1.43x
P/FCF (Annual)137.63x
Revenue / Share (TTM)$1.28
ROE (TTM)-90.62%
52-Week Low$1.49
vGradeD
gGradeB
mGradeA
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.05est. -0.11
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.18
4.18
4.20
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
APYXApyx Medical Corporation Common Stock | D | B | A | $4.47 |
| SYKStryker Corporation | C | C | C | $305.66 |
| MMM3M Company | C | F | C | $153.76 |
| BSXBoston Scientific Corp. | C | B | D | $48.55 |
| MDLNMedline Inc. Class A common stock | C | D | D | $33.61 |
| BDXBecton, Dickinson and Co. | B | C | C | $151.16 |
| RMDResMed Inc. | C | B | C | $196.04 |
| DXCMDexCom, Inc. | C | B | C | $72.86 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $314.50 |
| SOLVSolventum Corporation | C | D | B | $81.01 |
| PENPenumbra, Inc. | F | C | B | $320.53 |
About
Apyx Medical Corp manufactures energy-based medical devices for cosmetic and surgical markets. Its core products include Renuvion, a controlled heat technology used by plastic and cosmetic surgeons, and J-Plasma, a precision surgical system designed to minimize tissue damage. The company's Advanced Energy segment represents its primary revenue driver.